Cargando…

Efficacy and safety of fremanezumab for episodic migraine prevention: Multicenter, randomized, double‐blind, placebo‐controlled, parallel‐group trial in Japanese and Korean patients

OBJECTIVE: To evaluate the efficacy and safety of two dosing regimens of fremanezumab in Japanese and Korean patients with episodic migraine. BACKGROUND: Episodic migraine, which accounts for more than 90% of migraine cases, is inadequately addressed by widely available preventive therapies. Fremane...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sakai, Fumihiko, Suzuki, Norihiro, Kim, Byung‐Kun, Tatsuoka, Yoshihisa, Imai, Noboru, Ning, Xiaoping, Ishida, Miki, Nagano, Kaori, Iba, Katsuhiro, Kondo, Hiroyuki, Koga, Nobuyuki
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Research Submissions
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8457233/ https://www.ncbi.nlm.nih.gov/pubmed/34323290 http://dx.doi.org/10.1111/head.14178

Ejemplares similares

Efficacy and safety of fremanezumab for chronic migraine prevention: Multicenter, randomized, double‐blind, placebo‐controlled, parallel‐group trial in Japanese and Korean patients
por: Sakai, Fumihiko, et al.
Publicado: (2021)

Long-Term Safety and Tolerability of Fremanezumab for Migraine Preventive Treatment in Japanese Outpatients: A Multicenter, Randomized, Open-Label Study
por: Sakai, Fumihiko, et al.
Publicado: (2021)

Reduction in the severity and duration of headache following fremanezumab treatment in patients with episodic and chronic migraine
por: Ashina, Messoud, et al.
Publicado: (2021)

A Randomized Phase 2 Study of Erenumab for the Prevention of Episodic Migraine in Japanese Adults
por: Sakai, Fumihiko, et al.
Publicado: (2019)

Long‐term efficacy and safety during open‐label erenumab treatment in Japanese patients with episodic migraine
por: Sakai, Fumihiko, et al.
Publicado: (2021)

Reversion From Chronic Migraine to Episodic Migraine in Patients Treated With Fremanezumab: Post Hoc Analysis From HALO CM Study
por: Lipton, Richard B., et al.
Publicado: (2020)

Improvements in quality of life and work productivity with up to 6 months of fremanezumab treatment in patients with episodic and chronic migraine and documented inadequate response to 2 to 4 classes of migraine‐preventive medications in the phase 3b FOCUS study
por: Spierings, Egilius L. H., et al.
Publicado: (2021)

Effects of fremanezumab in patients with chronic migraine and comorbid depression: Subgroup analysis of the randomized HALO CM study
por: Lipton, Richard B., et al.
Publicado: (2021)

Fremanezumab for Episodic Migraine Prevention in Japanese Patients: Subgroup Analysis from Two International Trials
por: Saigoh, Kazumasa, et al.
Publicado: (2023)

Effect of Fremanezumab Monthly and Quarterly Doses on Efficacy Responses
por: Fiedler‐Kelly, Jill, et al.
Publicado: (2020)

Effects of Fremanezumab on Medication Overuse in Japanese Chronic Migraine Patients: Post Hoc Analysis of a Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial
por: Imai, Noboru, et al.
Publicado: (2023)

Erenumab treatment for migraine prevention in Japanese patients: Efficacy and safety results from a Phase 3, randomized, double‐blind, placebo‐controlled study
por: Takeshima, Takao, et al.
Publicado: (2021)

Early onset of efficacy with fremanezumab in patients with episodic and chronic migraine: subanalysis of two phase 2b/3 trials in Japanese and Korean patients
por: Takeshima, Takao, et al.
Publicado: (2022)

Development and validation of a novel patient‐reported outcome measure in people with episodic migraine and chronic migraine: The Activity Impairment in Migraine Diary
por: Lipton, Richard B., et al.
Publicado: (2021)

Fremanezumab for Chronic Migraine Prevention in Japanese Patients: Subgroup Analysis from Two International Trials
por: Saigoh, Kazumasa, et al.
Publicado: (2023)

No “Wearing‐Off Effect” Seen in Quarterly or Monthly Dosing of Fremanezumab: Subanalysis of a Randomized Long‐Term Study
por: Blumenfeld, Andrew M., et al.
Publicado: (2020)

Rapid Onset of Effect of Galcanezumab for the Prevention of Episodic Migraine: Analysis of the EVOLVE Studies
por: Detke, Holland C., et al.
Publicado: (2019)

Review of Tolerability of Fremanezumab for Episodic and Chronic Migraine
por: Root, Shane, et al.
Publicado: (2023)

Phase 2 randomized placebo‐controlled study of lasmiditan for the acute treatment of migraine in Japanese patients
por: Sakai, Fumihiko, et al.
Publicado: (2021)

Eptinezumab Demonstrated Efficacy in Sustained Prevention of Episodic and Chronic Migraine Beginning on Day 1 After Dosing
por: Dodick, David W., et al.
Publicado: (2020)

Real‐world persistence of erenumab for preventive treatment of chronic and episodic migraine: Retrospective real‐world study
por: Gladstone, Jonathan, et al.
Publicado: (2021)

The Spectrum of Response to Erenumab in Patients With Episodic Migraine and Subgroup Analysis of Patients Achieving ≥50%, ≥75%, and 100% Response
por: Broessner, Gregor, et al.
Publicado: (2020)

Psychometric Validation of the Role Function Restrictive Domain of the Migraine Specific Quality‐of‐Life Questionnaire Version 2.1 Electronic Patient‐Reported Outcome in Patients With Episodic and Chronic Migraine
por: Speck, Rebecca M., et al.
Publicado: (2019)

Psychometric validation and meaningful within‐patient change of the Migraine‐Specific Quality of Life questionnaire version 2.1 electronic patient‐reported outcome in patients with episodic and chronic migraine
por: Speck, Rebecca M., et al.
Publicado: (2021)

Fremanezumab for migraine
Publicado: (2020)

Analysis of Initial Nonresponders to Galcanezumab in Patients With Episodic or Chronic Migraine: Results From the EVOLVE‐1, EVOLVE‐2, and REGAIN Randomized, Double‐Blind, Placebo‐Controlled Studies
por: Nichols, Russell, et al.
Publicado: (2018)

Efficacy, Tolerability, and Safety of DFN‐15 (Celecoxib Oral Solution, 25 mg/mL) in the Acute Treatment of Episodic Migraine: A Randomized, Double‐Blind, Placebo‐Controlled Study
por: Lipton, Richard B., et al.
Publicado: (2019)

Family Impact of Migraine: Development of the Impact of Migraine on Partners and Adolescent Children (IMPAC) Scale
por: Lipton, Richard B., et al.
Publicado: (2017)

Characterization of Familial and Sporadic Migraine
por: Ravn, Julie, et al.
Publicado: (2019)

100% Response Rate to Galcanezumab in Patients With Episodic Migraine: A Post Hoc Analysis of the Results From Phase 3, Randomized, Double‐Blind, Placebo‐Controlled EVOLVE‐1 and EVOLVE‐2 Studies
por: Rosen, Noah, et al.
Publicado: (2018)

Most Bothersome Symptom in Persons With Migraine: Results From the Migraine in America Symptoms and Treatment (MAST) Study
por: Munjal, Sagar, et al.
Publicado: (2019)

A Qualitative Study to Assess the Content Validity of the 24‐Hour Migraine Quality of Life Questionnaire in Patients with Migraine
por: Speck, Rebecca M., et al.
Publicado: (2020)

Discontinuation of Acute Prescription Medication for Migraine: Results From the Chronic Migraine Epidemiology and Outcomes (CaMEO) Study
por: Lipton, Richard B., et al.
Publicado: (2019)

Life With Migraine: Effects on Relationships, Career, and Finances From the Chronic Migraine Epidemiology and Outcomes (CaMEO) Study
por: Buse, Dawn C., et al.
Publicado: (2019)

Comparison and predictors of chronic migraine vs. new daily persistent headache presenting with a chronic migraine phenotype
por: Nagaraj, Karthik, et al.
Publicado: (2022)

United States Patients’ Perspective of Living With Migraine: Country‐Specific Results From the Global “My Migraine Voice” Survey
por: Gibbs, Sarah N., et al.
Publicado: (2020)

The migraine signature study: Methods and baseline results
por: Pressman, Alice R., et al.
Publicado: (2020)

Assessing Barriers to Chronic Migraine Consultation, Diagnosis, and Treatment: Results From the Chronic Migraine Epidemiology and Outcomes (CaMEO) Study
por: Dodick, David W., et al.
Publicado: (2016)

Development of a New Tool for Evaluating the Benefit of Preventive Treatments for Migraine on Functional Outcomes – The Migraine Functional Impact Questionnaire (MFIQ)
por: Hareendran, Asha, et al.
Publicado: (2018)

The Effect of Psychiatric Comorbidities on Headache‐Related Disability in Migraine: Results From the Chronic Migraine Epidemiology and Outcomes (CaMEO) Study
por: Lipton, Richard B., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_ab41pt0e1vll99j8ip42of1evs